Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication

Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo

(2013) Xiang Zhou et al.   ANTI-CANCER DRUGS

Artesunate has its enhancement on antibacterial activity of β-lactams via increasing the antibiotic accumulation within methicillin-resistant Staphylococcus aureus (MRSA)

(2013) Weiwei Jiang et al.   JOURNAL OF ANTIBIOTICS

Global control of hepatitis C: where challenge meets opportunity

(2013) David L Thomas   NATURE MEDICINE

Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study

(2012) Robert Miller et al.   MALARIA JOURNAL

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

(2011) Jean-Michel Pawlotsky   HEPATOLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

An Artemisinin-Derived Dimer Has Highly Potent Anti-Cytomegalovirus (CMV) and Anti-Cancer Activities

(2011) Ran He et al.   PLoS One

Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: Role of TGF-β1 in HCV replication

(2011) Lance D. Presser et al.   VIROLOGY

Artemisinin-Derived Dimers Have Greatly Improved Anti-Cytomegalovirus Activity Compared to Artemisinin Monomers

(2010) Ravit Arav-Boger et al.   PLoS One

Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway

(2009) D. Burdette et al.   JOURNAL OF GENERAL VIROLOGY

The Antiviral Activities of Artemisinin and Artesunate

(2008) Thomas Efferth et al.   CLINICAL INFECTIOUS DISEASES

Qinghaosu (Artemisinin): The Price of Success

(2008) N. J. White   SCIENCE